Inventor · disambiguated record
Nathan Trinklein
Also filed as: TRINKLEIN NATHAN · TRINKLEIN NATHAN D
18 granted patents·27 pending applications·48 citations·filing 2006–2025
92Inventor score
Top patents by PatentIndex Score
45 records- 0194US11186639B2Multispecific heavy chain antibodies with modified heavy chain constant regionsTENEOONE INC·Filed 2021·Granted Nov 30, 2021·7 cites·20 claims
- 0293US11421027B2CD3 binding antibodiesTENEOONE INC·Filed 2021·Granted Aug 23, 2022·6 cites·17 claims
- 0393US11390681B2Multispecific heavy chain antibodies with modified heavy chain constant regionsTENEOTWO INC·Filed 2021·Granted Jul 19, 2022·8 cites·20 claims
- 0492US11505606B2CD3 binding antibodiesTENEOBIO INC·Filed 2017·Granted Nov 22, 2022·10 cites·30 claims
- 0586US11613572B2CD3 binding antibodiesTENEOBIO INC·Filed 2017·Granted Mar 28, 2023·4 cites·13 claims
- 0686US11434299B2Anti-BCMA heavy chain-only antibodiesTENEOBIO INC·Filed 2017·Granted Sep 6, 2022·4 cites·17 claims
- 0785US11427642B2Anti-BCMA heavy chain-only antibodiesTENEOONE INC·Filed 2018·Granted Aug 30, 2022·4 cites·13 claims
- 0884US11884735B2Agonistic anti-IL-2R antibodies and methods of useTENEOBIO INC·Filed 2023·Granted Jan 30, 2024·2 cites·25 claims
- 0983US2025066476A1Multispecific heavy chain antibodies with modified heavy chain constant regionsTENEOONE INC·Filed 2023·Application pending·0 cites
- 1082US11905326B2Multispecific heavy chain antibodies binding to CD22 and CD3TENEOBIO INC·Filed 2020·Granted Feb 20, 2024·2 cites·97 claims
- 1179US2023272075A1Cd3 binding antibodiesTENEOBIO INC·Filed 2022·Application pending·0 cites
- 1277US2025340638A1Cd3 binding antibodiesTENEOONE INC·Filed 2025·Application pending·0 cites
- 1377US2024117050A1Cd3-delta/epsilon heterodimer specific antibodiesTENEOBIO INC·Filed 2023·Application pending·0 cites
- 1477US2023082151A1Cd3 binding antibodiesTENEOONE INC·Filed 2022·Application pending·0 cites
- 1576US12371505B2Anti-BCMA heavy chain-only antibodiesTENEOBIO INC·Filed 2022·Granted Jul 29, 2025·0 cites·10 claims
- 1674US8815779B2Transcription biomarkers of biological responses and methodsALDRED SHELLEY FORCE·Filed 2009·Granted Aug 26, 2014·1 cites·31 claims
- 1774US2022332820A1Multispecific heavy chain antibodies with modified heavy chain constant regionsTENEOONE INC·Filed 2021·Application pending·0 cites
- 1872US2023203161A1Multispecific heavy chain antibodies with modified heavy chain constant regionsTENEOBIO INC·Filed 2021·Application pending·0 cites
- 1971US2024124599A1Anti-bcma heavy chain-only antibodiesTENEOBIO INC·Filed 2023·Application pending·0 cites
- 2068US2024018235A1Cd3 binding antibodiesTENEOBIO INC·Filed 2023·Application pending·0 cites
- 2167US2024117046A1Heavy chain antibodies binding to cd22TENEOBIO INC·Filed 2023·Application pending·0 cites
- 2267US2025179180A1Cd3-delta/epsilon heterodimer specific antibodiesTENEOBIO INC·Filed 2025·Application pending·0 cites
- 2366US2024368274A1Multispecific heavy chain antibodies binding to cd22 and cd3TENEOBIO INC·Filed 2024·Application pending·0 cites
- 2465US9663823B2Transcription biomarkers of biological responses and methods of useALDRED SHELLEY FORCE·Filed 2014·Granted May 30, 2017·0 cites·31 claims
- 2565US2025270337A1Anti-bcma heavy chain-only antibodiesTENEOBIO INC·Filed 2025·Application pending·0 cites
- 2665US2023060847A1Anti-bcma heavy chain-only antibodiesTENEOONE INC·Filed 2022·Application pending·0 cites
- 2765US2024117063A1Anti-cd20 antibodies and car-t structuresTENEOBIO INC·Filed 2023·Application pending·0 cites
- 2865US2024042032A1Anti-cd19 antibodies and car-t structuresTENEOBIO INC·Filed 2023·Application pending·0 cites
- 2965US2020339685A1Cd3-delta/epsilon heterodimer specific antibodiesTENEOBIO INC·Filed 2018·Application pending·0 cites
- 3061US2025346682A1Anti-cd20 antibodies and car-t structuresTENEOBIO INC·Filed 2025·Application pending·0 cites
- 3160US12202898B2Heavy chain antibodies binding to CD19TENEOTWO INC·Filed 2019·Granted Jan 21, 2025·0 cites·39 claims
- 3259US11970540B2Anti-BCMA heavy chain-only antibodiesTENEOBIO INC·Filed 2018·Granted Apr 30, 2024·0 cites·14 claims
- 3357US11873336B2Heavy chain antibodies binding to CD22TENEOBIO INC·Filed 2018·Granted Jan 16, 2024·0 cites·14 claims
- 3456US10663455B2Transcription biomarkers of biological responses and methods of useSWITCHGEAR GENOMICS INC·Filed 2017·Granted May 26, 2020·0 cites·31 claims
- 3555US2024002498A1Heavy chain antibodies binding to folate receptor alphaTENEOBIO INC·Filed 2021·Application pending·0 cites
- 3655US2024226162A9Anti-psma antibodies and car-t structuresTENEOBIO INC·Filed 2022·Application pending·0 cites
- 3755US2023257473A1Multi-specific antibodies binding to bcmaTENEOBIO INC·Filed 2021·Application pending·0 cites
- 3851US12495776B2Transgenic non-human animals producing modified heavy chain-only antibodiesTENEOBIO INC·Filed 2017·Granted Dec 16, 2025·0 cites·14 claims
- 3950US2020138865A1Anti-b-cell maturation antigen chimeric antigen receptors with human domainsUS HEALTH·Filed 2018·Application pending·0 cites
- 4050US2024182597A1Anti-muc1-c antibodies and car-t structuresTENEOBIO INC·Filed 2022·Application pending·0 cites
- 4149US2007161031A1Functional arrays for high throughput characterization of gene expression regulatory elementsUNIV LELAND STANFORD JUNIOR·Filed 2006·Application pending·0 cites
- 4247US2009018031A1Transcriptional regulatory elements of biological pathways tools, and methodsSWITCHGEAR GENOMICS·Filed 2007·Application pending·0 cites
- 4347US2008220983A1Functional arrays for high throughput characterization of regulatory elements in untranslated regions of genesSWITCHGEAR GENOMICS A CALIFORN·Filed 2008·Application pending·0 cites
- 4442US9006405B2Modified renilla luciferase nucleic acids and methods of useTRINKLEIN NATHAN D·Filed 2011·Granted Apr 14, 2015·0 cites·41 claims
- 4541US2020207867A1Heavy chain antibodies binding to ectoenzymesTENEOBIO INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nathan Trinklein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →